title: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
abstract: Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.
authors.affiliation: Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Heinzerling
authors.forename: Sergio
authors.initials: S
authors.lastname: Huerta
mesh_terms: D000006:Abdomen, Acute / Q000139:chemically induced*; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab